2 completed, 1 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Gastrointestinal Tumor: new trials by email Literature Review of Gastrointestinal Tumor trials Research Report on Gastrointestinal Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany), tislelizumab (BeiGene, China) combined with PD-1 inhibitor - Gastrointestinal Tumor | Phase 1 / Phase 2 | Completed | Pengyuan Liu | 18 | 2020-06-01 | 2023-09-05 |
| Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors Pyrotinib with or without trastuzumab - Gastrointestinal Tumor, Effect of Drug | Phase 2 | Unknown | Fudan University | 60 | 2020-02-01 | 2021-07-14 |
| Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma Cisplatin, Gemcitabine, Copanlisib - Biliary Carcinoma, Gall Bladder Carcinoma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 24 | 2016-07-05 | 2021-08-04 |
Digestive System Neoplasms (3) · Cholangiocarcinoma (1) · Gallbladder Neoplasms (1) · Hyperthermia (1) · Neoplasm Metastasis (1)
Digestive System Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Pathological Conditions, Signs and Symptoms (2) · Adenocarcinoma (1) · Biliary Tract Diseases (1) · Biliary Tract Neoplasms (1) · Body Temperature Changes (1) · Carcinoma (1) · Gallbladder Diseases (1) · Heat Stress Disorders (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Neoplastic Processes (1) · Pathologic Processes (1)
Cisplatin (1) · Gemcitabine (1) · Immune Checkpoint Inhibitors (1) · Trastuzumab (1) · copanlisib (1) · pyrotinib (1) · spartalizumab (1) · tislelizumab (1)
Fudan University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Pengyuan Liu (1)
China (2) · United States (1)
Jun Chen (1) · Richard D. Kim, M.D. (1) · Xiaodong Zhu, phD (1)